Drug Profile
Research programme: JAK3 kinase inhibitors - Novartis
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cytopia Research
- Developer Novartis
- Class Small molecules
- Mechanism of Action Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Transplant rejection
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Switzerland (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Transplant-rejection in Switzerland (PO)
- 13 Jul 2010 Preclinical development is ongoing in Switzerland